Searching for ways to beat back rising drug costs, the Chilean legislature is advancing three measures — regulating prices, easing the mechanism for issuing a compulsory license, and creating a government web site to monitor pricing —that have alarmed the pharmaceutical industry.

One of the initiatives in particular has drug makers concerned. The proposed law, which last week passed the Health Commission, will allow the government to determine the price of a patented medicine based on whether the buyers have “economic accessibility.” In other words, if the drug is priced out of reach, the health ministry will have the right to cap its price.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy